Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned an average rating of “Hold” from the twelve analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $21.00.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Tuesday. ValuEngine downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Cantor Fitzgerald set a $27.00 price objective on Halozyme Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 6th. Finally, Piper Jaffray Companies assumed coverage on Halozyme Therapeutics in a report on Thursday, October 18th. They set a “hold” rating and a $17.00 price objective on the stock.

In other news, major shareholder Randal J. Kirk sold 161,246 shares of the business’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $17.15, for a total value of $2,765,368.90. Following the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at approximately $61,094,954.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Randal J. Kirk sold 1,194,462 shares of the business’s stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $17.65, for a total value of $21,082,254.30. Following the completion of the transaction, the insider now directly owns 3,562,388 shares in the company, valued at $62,876,148.20. The disclosure for this sale can be found here. Insiders sold a total of 2,000,706 shares of company stock worth $35,509,187 over the last three months. 16.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its position in Halozyme Therapeutics by 69.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 22,346 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 9,134 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $21,690,000. Rhumbline Advisers raised its position in Halozyme Therapeutics by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 132,784 shares of the biopharmaceutical company’s stock worth $2,240,000 after purchasing an additional 8,703 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 76.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 643,822 shares of the biopharmaceutical company’s stock worth $10,862,000 after purchasing an additional 277,953 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Halozyme Therapeutics by 60.3% in the 2nd quarter. Wells Fargo & Company MN now owns 535,697 shares of the biopharmaceutical company’s stock worth $9,038,000 after purchasing an additional 201,507 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ HALO traded down $0.34 during trading on Friday, reaching $15.86. 12,674 shares of the company traded hands, compared to its average volume of 1,005,357. The company has a current ratio of 3.09, a quick ratio of 2.96 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of 35.62 and a beta of 1.88. Halozyme Therapeutics has a 1-year low of $14.33 and a 1-year high of $21.48.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. The company had revenue of $25.60 million for the quarter, compared to the consensus estimate of $30.42 million. Halozyme Therapeutics had a return on equity of 18.87% and a net margin of 16.24%. The company’s quarterly revenue was down 59.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.02 earnings per share. On average, analysts predict that Halozyme Therapeutics will post -0.59 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Recommended Story: Treasury Bonds

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.